Title:
がんの治療のための方法、組成物、及びキット
Document Type and Number:
Japanese Patent JP6774421
Kind Code:
B2
Abstract:
Provided herein are the use of FGFR3 inhibitors and PD1 inhibitors to treat solid and hematologic cancers and compositions and kits comprising an FGFR3 inhibitor and a PD1 inhibitor.
Inventors:
Horash, joslin
Lau, Stephen
Lau, Stephen
Application Number:
JP2017544657A
Publication Date:
October 21, 2020
Filing Date:
February 19, 2016
Export Citation:
Assignee:
Fusion Pharmaceuticals, Inc.
International Classes:
A61K39/395; A61P35/00; A61P43/00
Domestic Patent References:
| JP2012521759A |
Other References:
CHAMPIAT, S., et al.,Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC,Journal of Thoracic Oncology,2014年 2月,Vol.9, No.2,pp.144-153.
LUKE, J. J., et al.,Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advenced cancer: synergistic or antagonistic?,Expert Opinion on Pharmacotherapy,2013年10月21日,Vol.14, No,18,pp.2457-2462.
CHEN, S., et al.,Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cell in a poorly immunogenic tumor model,Cancer Immunology Research,2014年11月11日,Vol.3, No.2,pp.149-160.
STAGG, J., et al.,Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy,Proceedings of the National Academy of Sciences,2011年 4月26日,Vol.108, No.17,pp7142-7147
MOMTAZ, P., et al.,Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway,Pharmacogenomics and Personalized Medicine,2014年,Vol.7,pp.357-365.
AZIJLI, K., et al.,New develoopments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies,Anticancer Research,2014年,Vol.34,pp.1493-1506
TYKODI, S. S.,PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence,OncoTargets and Therapy,2014年,Vol.7,pp.1349-1359.
LUKE, J. J., et al.,Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advenced cancer: synergistic or antagonistic?,Expert Opinion on Pharmacotherapy,2013年10月21日,Vol.14, No,18,pp.2457-2462.
CHEN, S., et al.,Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cell in a poorly immunogenic tumor model,Cancer Immunology Research,2014年11月11日,Vol.3, No.2,pp.149-160.
STAGG, J., et al.,Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy,Proceedings of the National Academy of Sciences,2011年 4月26日,Vol.108, No.17,pp7142-7147
MOMTAZ, P., et al.,Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway,Pharmacogenomics and Personalized Medicine,2014年,Vol.7,pp.357-365.
AZIJLI, K., et al.,New develoopments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies,Anticancer Research,2014年,Vol.34,pp.1493-1506
TYKODI, S. S.,PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence,OncoTargets and Therapy,2014年,Vol.7,pp.1349-1359.
Attorney, Agent or Firm:
Sonoda/Kobayashi Patent Business Corporation